text: Yo, check it out, I got a story to tell
  'Bout the structural optimization, can you hear me well?
  We talkin' 'bout them compounds, 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl
  Potential inhibitors, EGFR, they're the real deal
  
  We wanted better pharmacokinetic properties, you see
  So we optimized these compounds, that's the key
  Compound 2v came out on top, no doubt
  Improved solubility, pharmacokinetics with clout
  
  It's a nanomolar inhibitor, potent and strong
  Blocking gefitinib-resistant EGFR all day long
  Got that antiproliferative activity, for real
  Against H1975 nonsmall cell lung cancer, it's a big deal
  
  But wait, there's more, let me tell you the rest
  In a murine model, this inhibitor impressed
  No effect on body weight, it's all good
  Showing antitumor efficacy like we knew it would
  
  So listen up, these studies pave the way
  Lead compounds for treatment, we're here to stay
  Gefitinib-resistant nonsmall cell lung cancer, we won't back down
  We're bringing new drugs, gonna turn this around